BF0801, a novel adenine derivative, inhibits platelet activation via phosphodiesterase inhibition and P2Y 12 antagonism

Thrombosis and Haemostasis

Volumn 104, Issue 4, 2010, Pages 845-857

  Zhang, Si ^a   Hu, Liang ^a   Du, Hongguang ^b   Guo, Yan ^c   Zhang, Yan ^a   Niu, Haixia ^d   Jin, Jianguo ^e   Zhang, Jian ^d   Liu, Junling ^d   Zhang, Xiaohui ^c   Kunapuli, Satya P ^e   Ding, Zhongren ^a  

^a FUDAN UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF CHEMICAL TECHNOLOGY   (China)

^c INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^e TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenine derivative; Antiplatelet; cAMP; P2Y 12; Phosphodiesterase

Indexed keywords

4 [[3,4 (METHYLENEDIOXY) BENZYL]AMINO] 6 CHLOROQUINAZOLINE; 9 (2 HYDROXY 3 NONYL) ADENINE; ADENOSINE TRIPHOSPHATE; ADENYLATE CYCLASE; ANTITHROMBOCYTIC AGENT; BF0801; CANGRELOR; CILOSTAMIDE; CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE; ISOBUTYLMETHYLXANTHINE; PHOSPHODIESTERASE; PHOSPHODIESTERASE V INHIBITOR; PROPIONIC ACID 2 (6 AMINO 2 (PROPYLTHIO) PURIN 9 YL) ETHYL ESTER; PROTEIN KINASE B; PURINERGIC P2Y12 RECEPTOR; UNCLASSIFIED DRUG; ADENINE; ADENOSINE PHOSPHATE; DRUG DERIVATIVE; P2RY12 PROTEIN, HUMAN; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTICOAGULATION; ARTICLE; ATOMIC FORCE MICROSCOPY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RAT; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE RELEASE REACTION; ANIMAL; BIOSYNTHESIS; CHO CELL; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; CRICETULUS; DRUG EFFECT; GENETICS; HAMSTER; METABOLISM; MOUSE MUTANT; PATHOLOGY; SPRAGUE DAWLEY RAT; THROMBOCYTE;

ADENINE; ADENOSINE MONOPHOSPHATE; ADENOSINE TRIPHOSPHATE; ANIMALS; BLOOD PLATELETS; CHO CELLS; CORONARY ARTERY DISEASE; CRICETINAE; CRICETULUS; HUMANS; MICE; MICE, KNOCKOUT; PHOSPHORIC DIESTER HYDROLASES; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PURINERGIC P2Y12;

EID: 79955859077     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-05-0285     Document Type: Article

References (46)

1. Zurn CS, Geisler T, Gawaz M. ADP-receptor blockade: A case for personalised pharmacotherapy? Thromb Haemost 2010; 103: 496-506.
2. Han Y, Li Y, Wang S, et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J 2009; 157: 733-739.
3. Daniel JL, Dangelmaier C, Jin J, et al. Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J Biol Chem 1998; 273: 2024-2029.
4. Jin J, Daniel JL, Kunapuli SP. Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem 1998; 273: 2030-2034.
5. Barrabes JA, Inserte J, Mirabet M, et al. Antagonism of P2Y12 or GPIIb/IIIa receptors reduces platelet-mediated myocardial injury after ischaemia and reperfusion in isolated rat hearts. Thromb Haemost 2010;104: 128-135.
6. Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. J Clin Invest 2004; 113: 340-345.
7. Jin J, Kunapuli SP. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci USA 1998; 95: 8070-8074.
8. Zu L, Jiang H, He J, et al. Salicylate blocks lipolytic actions of tumor necrosis factor-alpha in primary rat adipocytes. Mol Pharmacol 2008; 73: 215-223.
9. Foster CJ, Prosser DM, Agans JM, et al. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 2001; 107: 1591-1598.
10. Liu J, Joglekar M, Ware J, et al. Evaluation of the physiological significance of botrocetin/ von Willebrand factor in vitro signaling. J Thromb Haemost 2008; 6: 1915-1922.
11. Shankar H, Murugappan S, Kim S, et al. Role of G protein-gated inwardly-rectifying potassium channels in P2Y12 receptor-mediated platelet functional responses. Blood 2004; 104: 1335-1343.
12. Ding Z, Bynagari YS, Mada SR, et al. Studies on the role of the extracellular cysteines and oligomeric structures of the P2Y receptor when interacting with antagonists. J Thromb Haemost 2009; 7: 232-234.
13. Ding ZR, Huang SJ, Sun JJ. Induction of platelet activation by cobra venom factor from Naja naja atra in rat. Acta Pharmacol Sin 2000; 21: 649-654.
14. Liu J, Pestina TI, Berndt MC, et al. The roles of ADP and TXA in botrocetin/VWFinduced aggregation of washed platelets. J Thromb Haemost 2004; 2: 2213-2222.
15. Shankar H, Kahner BN, Prabhakar J, et al. G-protein-gated inwardly rectifying potassium channels regulate ADP-induced cPLA2 activity in platelets through Src family kinases. Blood 2006; 108: 3027-3034.
16. Ding Z, Kim S, Kunapuli SP. Identification of a potent inverse agonist at a constitutively active mutant of human P2Y12 receptor. Mol Pharmacol 2006; 69: 338-345.
17. Ma T, Zhu X. Interleukin-6 increases the levels of cyclic GMP and nitrite in rat hippocampal slices. Eur J Pharmacol 1997; 321: 343-347.
18. Spoto G, Whitehead E, Ferraro A, et al. A reverse-phase HPLC method for cAMP phosphodiesterase activity. Analyt Biochem 1991; 196: 207-210.
19. Tang HF, Song YH, Chen JC, et al. Upregulation of phosphodiesterase-4 in the lung of allergic rats. Am J Resp Crit Care Med 2005; 171: 823-828.
20. Horber JK, Miles MJ. Scanning probe evolution in biology. Science (NY) 2003; 302: 1002-1005.
21. Hinterdorfer P, Dufrene YF. Detection and localization of single molecular recognition events using atomic force microscopy. Nature Methods 2006; 3: 347-355.
22. Quinton TM, Ozdener F, Dangelmaier C, et al. Glycoprotein VI-mediated platelet fibrinogen receptor activation occurs through calcium-sensitive and PKC-sensitive pathways without a requirement for secreted ADP. Blood 2002; 99: 3228-3234.
23. Kim S, Foster C, Lecchi A, et al. Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling. Blood 2002; 99: 3629-3636.
24. Atkinson BT, Stafford MJ, Pears CJ, et al. Signalling events underlying platelet aggregation induced by the glycoprotein VI agonist convulxin. Eur J Biochem/FEBS 2001; 268: 5242-5248.
25. Ingall AH, Dixon J, Bailey A, et al. Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy. J Med Chem 1999; 42: 213-220.
26. Liu FC, Liao CH, Chang YW, et al. A new insight of anti-platelet effects of sirtinol in platelets aggregation via cyclic AMP phosphodiesterase. Biochem Pharmacol 2009; 77: 1364-1373.
27. Omori K, Kotera J. Overview of PDEs and their regulation. Circ Res 2007; 100: 309-327.
28. Sun B, Li H, Shakur Y, et al. Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice. Cell Signal 2007; 19: 1765-1771.
29. Podzuweit T, Nennstiel P, Muller A. Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenine. Cell Signal 1995; 7: 733-738.
30. Andre P, Delaney SM, LaRocca T, et al. P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest 2003; 112: 398-406.
31. Kim S, Jin J, Kunapuli SP. Akt activation in platelets depends on Gi signaling pathways. J Biol Chem 2004; 279: 4186-4195.
32. Hayashi H, Sudo T. Effects of the cAMP-elevating agents cilostamide, cilostazol and forskolin on the phosphorylation of Akt and GSK-3beta in platelets. Thromb Haemost 2009; 102: 327-335.
33. Costanzi S, Mamedova L, Gao ZG, et al. Architecture of P2Y nucleotide receptors: structural comparison based on sequence analysis, mutagenesis, and homology modeling. J Med Chem 2004; 47: 5393-5404.
34. Humphries RG, Robertson MJ, Leff P. A novel series of P2T purinoceptor antagonists: definition of the role of ADP in arterial thrombosis. Trends Pharmacol Sci 1995; 16: 179-181.
35. Florin EL, Moy VT, Gaub HE. Adhesion forces between individual ligand-receptor pairs. Science (NY) 1994; 264: 415-417.
36. Zhang X, Craig SE, Kirby H, et al. Molecular basis for the dynamic strength of the integrin alpha4beta1/VCAM-1 interaction. Biophys J 2004; 87: 3470-3478.
37. Muller DJ, Helenius J, Alsteens D, et al. Force probing surfaces of living cells to molecular resolution. Nature Chem Biol 2009; 5: 383-390.
38. Helenius J, Heisenberg CP, Gaub HE, et al. Single-cell force spectroscopy. J Cell Sci 2008; 121: 1785-1791.
39. Zhang X, Chen A, De Leon D, et al. Atomic force microscopy measurement of leukocyte-endothelial interaction. Am J Physiol 2004; 286: H359-367.
40. Lee I, Marchant RE. Molecular interaction studies of hemostasis: fibrinogen ligand-human platelet receptor interactions. Ultramicroscopy 2003; 97: 341-352.
41. Cattaneo M, Lecchi A. Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin. J Thromb Haemost 2007; 5: 577-582.
42. Dickinson NT, Jang EK, Haslam RJ. Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: effects on platelet aggregation. Biochem J 1997; 323: 371-377.
43. Ishii H, Kojima Y, Masuda Y, et al. Expression of thrombin-activatable fibrinolysis inhibitor (TAFI) is up-regulated by increase in intracellular cyclic AMP levels in cultured HepG2 cells. Thromb Haemost 2009; 102: 1204-1211.
44. Lee SW, Park SW, Yun SC, et al. Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry). Am Heart J 2010; 159: 284-291 e1
45. Jeong YH, Lee SW, Choi BR, et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J Am Coll Cardiol 2009; 53: 1101-1109.
46. Lee JM, Park S, Shin DJ, et al. Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans. Am J Cardiol 2009; 104: 46-51.